Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments

#1496

Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma

Aim(s): To determine the efficacy of the above alternate sequence therapy in well and moderate-differentiated pancreatic neuroendocrine tumors (pNENs)

Materials and methods: Thirty-one patients were administered one compound and upon progression were changed to the other. All patients had grade 1 or 2 tumors, stage IV disease with similar metastatic pattern and had been exposed to similar therapies. Progression-free survival (PFS), estimate overall survival (OS) and the development of adverse events (AEs) were the primary end points.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Angelousi A, Kampel K, O'Toole D, Kaltsatoy M, Boutzios G,

Keywords: everolimus, sunitinib, pancreatic NETs,